Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects

INTRODUCTION: LC350189 is a novel selective xanthine oxidase inhibitor under clinical development for the management of hyperuricemia in gout patients. The aim of this study was to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of the drug in healthy subjects. METHODS: A dose-bloc...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Seonghae, Shin, Donghoon, Lee, Howard, Jang, In-Jin, Yu, Kyung-Sang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560520/
https://www.ncbi.nlm.nih.gov/pubmed/26357467
http://dx.doi.org/10.2147/DDDT.S86884

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560520/
https://www.ncbi.nlm.nih.gov/pubmed/26357467
http://dx.doi.org/10.2147/DDDT.S86884

Ejemplares similares